Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 57.0% in October

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 6,500 shares, a decrease of 57.0% from the October 15th total of 15,100 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 127,000 shares, the days-to-cover ratio is currently 0.1 days.

Estrella Immunopharma Price Performance

Shares of NASDAQ ESLA traded up $0.04 during mid-day trading on Wednesday, hitting $0.84. The company had a trading volume of 5,995 shares, compared to its average volume of 78,401. The company has a market capitalization of $30.40 million, a PE ratio of -0.39 and a beta of 0.24. The business’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.10. Estrella Immunopharma has a 1-year low of $0.63 and a 1-year high of $3.23.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings results on Friday, September 27th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.